HC Wainwright Has Optimistic Outlook of COYA FY2024 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Coya Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.13) per share for the year, up from their prior estimate of ($1.38). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.68) EPS.

Separately, Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Trading Down 0.1 %

COYA opened at $7.24 on Thursday. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The firm has a 50-day moving average price of $7.10 and a two-hundred day moving average price of $7.02. The stock has a market capitalization of $120.98 million, a PE ratio of -11.14 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15.

Insider Buying and Selling at Coya Therapeutics

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $7.34 per share, with a total value of $36,700.00. Following the completion of the transaction, the chief executive officer now owns 5,000 shares in the company, valued at approximately $36,700. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after acquiring an additional 750,338 shares during the period. Renaissance Technologies LLC acquired a new stake in Coya Therapeutics during the second quarter worth approximately $101,000. GHP Investment Advisors Inc. bought a new stake in shares of Coya Therapeutics during the 3rd quarter valued at $169,000. Finally, Gilbert & Cook Inc. acquired a new stake in Coya Therapeutics during the second quarter worth about $61,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.